Epigenetic changes driven by environmental pollutants in lung carcinogenesis: a comprehensive review.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 21 04 2024
accepted: 30 09 2024
medline: 23 10 2024
pubmed: 23 10 2024
entrez: 23 10 2024
Statut: epublish

Résumé

Lung cancer remains the leading cause of cancer-related mortality globally, with environmental pollutants identified as significant risk factors, especially for nonsmokers. The intersection of these pollutants with epigenetic mechanisms has emerged as a critical area of interest for understanding the etiology and progression of lung cancer. Epigenetic changes, including DNA methylation, histone modifications, and non-coding RNAs, can induce alterations in gene expression without affecting the DNA sequence and are influenced by environmental factors, contributing to the transformation of normal cells into malignant cells. This review assessed the literature on the influence of environmental pollutants on lung cancer epigenetics. A comprehensive search across databases such as PubMed, Web of Science, Cochrane Library, and Embase yielded 3,254 publications, with 22 high-quality papers included for in-depth analysis. These studies demonstrated the role of epigenetic markers, such as DNA methylation patterns of genes like F2RL3 and AHRR and alterations in the miRNA expression profiles, as potential biomarkers for lung cancer diagnosis and treatment. The review highlights the need to expand research beyond homogenous adult male groups typically found in high-risk occupational environments to broader population demographics. Such diversification can reduce biases and enhance the relevance of findings to various clinical contexts, fostering the development of personalized preventive and therapeutic measures. In conclusion, our findings underscore the potential of innovative epigenetic therapies, such as DNA demethylating drugs and histone modification agents, to counter environmental toxins' carcinogenic effects. The growing interest in miRNA therapies and studies aiming to correct aberrant methylation patterns indicate significant strides toward better lung cancer management and a healthier future for global communities.

Identifiants

pubmed: 39440184
doi: 10.3389/fpubh.2024.1420933
pmc: PMC11493668
doi:

Substances chimiques

Environmental Pollutants 0
MicroRNAs 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1420933

Informations de copyright

Copyright © 2024 Zhang, Luo, Li, Yan, Lai, Yang, Zhao, Huang, Li, Wu and Wang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Aijia Zhang (A)

Faculty of Humanities and Arts, Macau University of Science and Technology, Taipa, Macau SAR, China.

Xuexing Luo (X)

Faculty of Humanities and Arts, Macau University of Science and Technology, Taipa, Macau SAR, China.

Yu Li (Y)

State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.

Lunchun Yan (L)

Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.
Department of Comprehensive Surgery, Hengqin Hospital, The First Affiliated Hospital of Guangzhou Medical University, Guangdong-Macao in-Depth Cooperation Zone in Hengqin, Hengqin, China.

Xin Lai (X)

Department of Traditional Chinese Medicine, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Qianxu Yang (Q)

Centre for Epidemiology and Evidence-Based Practice, Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

Ziming Zhao (Z)

State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.

Guanghui Huang (G)

Faculty of Humanities and Arts, Macau University of Science and Technology, Taipa, Macau SAR, China.

Zheng Li (Z)

Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou, Jiangsu Province, China.
State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.

Qibiao Wu (Q)

State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.
Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangzhou, Guangdong Province, China.

Jue Wang (J)

State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
Faculty of Chinese Medicine, Macau University of Science and Technology, Taipa, Macau SAR, China.
Guangdong-Hong Kong-Macao Joint Laboratory for Contaminants Exposure and Health, Guangzhou, Guangdong Province, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH